The latest clinical evidence on PARP inhibitor maintenance therapy - ppt download
Niraparib Prolongs PFS in Patients with Newly Diagnosed Advanced
Inhibidores de PARP en primera línea de cáncer de ovario | PPT
Efficacy | ZEJULA (niraparib) for HCPs
Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial
Efficacy | ZEJULA (niraparib) for HCPs
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer | NEJM
OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab - ScienceDirect
Efficacy of niraparib in the PRIMA trial | Download Scientific Diagram
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer | NEJM
Efficacy of niraparib by timing of surgery and residual disease: a post-hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study - Gynecologic Oncology
Niraparib Efficacy and Safety in Patients with BRCA-Mutated (BRCAm) Ovarian Cancer: Results from Three Phase 3 Niraparib Trials
Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial - Maria-Pilar Barretina-Ginesta, Bradley J. Monk, Sileny Han, Bhavana
PRIMA study design. CR complete response, PR partial response, PFS... | Download Scientific Diagram
PARP inhibitor in Ca Ovary | PPT
Niraparib in the PRIMA Trial
Progression-free survival and safety at 3.5 years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer - European Journal of
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer | NEJM
Personalized Dosing of Niraparib in Ovarian Cancer - YouTube
Progression-free survival and safety at 3.5 years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer - ScienceDirect
Zejula (Niraparib) First PARP Inhibitor Approved for First-Line Maintenance Therapy in All Women with Advanced Ovarian Cancer, Regardless of Biomarker Status
Niraparib treatment for patients with BRCA-mutated ovarian cancer: review of clinical data and therapeutic context | Future Oncology
